The GZF1 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population derived from the widely used HeLa cervical adenocarcinoma cell line. This product features targeted disruption of the GZF1 gene, which encodes a BTB/POZ domain-containing zinc finger transcriptional repressor. The polyclonal format provides a heterogeneous knockout pool, offering a robust loss-of-function model for studying GZF1-dependent regulatory mechanisms without the need for single-cell cloning. These cells are suitable for a variety of functional genomics applications, including gene expression analysis, signaling pathway interrogation, and phenotypic screening.
HeLa cells were originally isolated from a cervical adenocarcinoma and are positive for human papillomavirus type 18 (HPV18). As an immortalized epithelial cell line, HeLa has become a cornerstone of biomedical research, particularly in cancer biology, virology, and signal transduction studies. The epithelial origin and transformed phenotype make HeLa cells a relevant host for investigating oncogenic signaling, cell cycle regulation, and apoptotic pathways. The GZF1 knockout in this background provides a controlled system to dissect the gene’s role in cervical cancer-related processes.
GZF1 functions as a transcriptional repressor activated by the GDNF/RET signaling pathway. Upon activation, GZF1 translocates to the nucleus, where it binds to target gene promoters, such as NTRK2 (encoding TrkB), through its C2H2 zinc finger domains. It then recruits corepressor complexes containing HDAC1, CoREST, SIN3A, and NCoR to silence transcription. This repression attenuates neurotrophin signaling downstream of BDNF/TrkB, thereby modulating cell survival, differentiation, and proliferation. GZF1 is also regulated by retinoic acid, EGF, and NGF, and its downstream targets include HOXA10, BCL2L1, and CCND1, linking it to cell cycle and apoptotic control. The interplay between GZF1 and interacting partners like Rb1 further integrates it into broader regulatory networks.
In the HeLa cervical adenocarcinoma context, GZF1 knockout cells enable dissection of its role in oncogenesis and tumor suppression. GZF1 has been implicated in cervical cancer, acute myeloid leukemia, neuroblastoma, and squamous cell carcinoma, making this model valuable for comparative oncology studies. By disrupting GZF1-mediated repression of NTRK2 and other targets, researchers can explore how loss of this repressor affects cell proliferation, migration, and drug sensitivity. The model is particularly relevant for studying retinoic acid and neurotrophin signaling in epithelial cancers, where these pathways are often dysregulated.
These polyclonal knockout cells are suited for a range of experimental applications, including chromatin immunoprecipitation (ChIP-qPCR) to assess promoter binding, reporter gene assays to measure transcriptional activity, and RT-qPCR or Western blotting for expression analysis. Functional assays such as cell proliferation, apoptosis, migration/invasion, and drug sensitivity testing can be used to evaluate phenotypic consequences of GZF1 loss. Additionally, the cells support studies of GDNF/RET and NTRK2/BDNF signaling crosstalk. For further information or technical support, please contact Ascent Research.
